All In Biotech

Drug Trial Radar · NCT05717920

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

The ADRO Trial: An Adaptive, 2-Part, Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Adults With Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

8

Actual

Start

Feb 15, 2023

Primary completion

Nov 21, 2023

Study completion Nov 21, 2023

Sponsor

Lead sponsor
Aldeyra Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.

Conditions

  • Atopic Dermatitis

Interventions

  • ADX-629 (Open-label)Drug

    ADX-629 (250 mg) administered twice daily for 90 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Serious Adverse EventsTime frame: The safety assessment period was approximately 15 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bexley Dermatology Research

    Bexley, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.